You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 157 No. 14, 28 JULY 1997 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL INVESTIGATIONS
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (7)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Efficacy of Nefopam for the Prevention and Treatment of Amphotericin B—Induced Shivering

Giovanni Rosa, MD; Donatella Dell'Utri, MD; Giorgio Conti, MD; Paolo Pelaia, MD; Alessandro Cogliati, MD; Paolo Orsi, MD; Alessandro Gasparetto, MD

Arch Intern Med. 1997;157(14):1589-1592.


Abstract

Background
Shivering is experienced by up to 70% of patients undergoing amphotericin B therapy. Treatment with meperidine hydrochloride, currently the most widely used medication for controlling amphotericin B—induced shivering, was compared with nefopam hydrochloride, which has been successfully used to treat post-operative shivering.

Methods
Forty-five patients with cancer and systemic fungal infections randomly received nefopam hydrochloride, 0.3 mg/kg, meperidine hydrochloride, 0.7 mg/kg, or saline solution intravenously 15 minutes before the cessation of amphotericin B infusion (1 mg/kg for 45 minutes). If shivering persisted, patients in the control (saline solution) group received either nefopam hydrochloride, 0.3 mg/kg, or meperidine hydrochloride, 0.7 mg/kg.

Results
Occurrence of shivering 15 minutes after the cessation of amphotericin B infusion was significantly less frequent in the nefopam (6.6%) and meperidine (40%) groups compared with the control group (66.6%). The incidence of shivering in the nefopam group with respect to the meperidine group was also significantly reduced. Moreover, nefopam administration to 5 persistently shivering patients in the control group definitively stopped the shivering in all of them (100%) in a mean (±SD) time of 29.1±4.8 seconds, while meperidine terminated shivering in 4 (80%) of 5 patients in a mean (±SD) time of 200.0±30.2 seconds. The adverse reactions that can be ascribed to nefopam or meperidine use were nausea and sedation, respectively, and may be considered negligible.

Conclusion
Nefopam seems to be more effective than meperidine in preventing and quickly suppressing amphotericin B—induced shivering.

Arch Intern Med. 1997;157:1589-1592



Author Affiliations

From the Institute of Anesthesia and Intensive Care, University La Sapienza, Rome (Drs Rosa, Dell'Utri, Conti, Cogliati, Orsi, and Gasparetto), and the Institute of Anesthesia and Intensive Care, University of Trieste, Trieste (Dr Pelaia), Italy.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Nefopam for Severe Hiccups
Bilotta and Rosa
NEJM 2000;343:1973-1974.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1997 American Medical Association. All Rights Reserved.